Synthetic HLA binding peptide analogues and uses thereof

Details Synthetic HLA binding peptide analogues and uses thereof Synthetic HLA binding peptide analogues and uses thereof

2004-11-30

2009-02-10

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S328000

Reexamination Certificate

active

07488718

ABSTRACT:
The present invention provides synthetic peptides comprising at least analogues of a native peptide that specifically bind to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state, such as a cancer cell, in a mammal. Also provided are pharmaceutical compositions and immunogenic compositions comprising at least the peptide analogue segments or a DNA encoding the same. Also provided are methods of using the synthetic peptides and immunogenic compositions to induce a heteroclitic immune response or to treat a cancer.

REFERENCES:
patent: 6156316 (2000-12-01), Scheinberg et al.
patent: WO 01/62920 (2001-08-01), None
Nieda, M , et al., Dendritic cells stimulate the expansion of bcr-abi specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia Blood. 1998 91(3): p. 977-83.
ten Bosch, G J., et al , A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an li(b2a2) construct Blood. 1999 94(3): p. 1038-45.
Yotnda, P , et al , Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia J Clin Invest, 1998 101(10): p. 2290-6.
Pinilla-Ibarz. J., et al, Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000 95(5): p. 1781-7.
Cathcart. K . et al . All CML patients vaccinated with a multivalent bcr-abl peptide vaccine show specific immune responses in a phase II trial Blood. 2001 98(11): p. 728a-728a.
Cathcart. K , et al., A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia Blood. 2003.
Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, et al Heteroclitic immunization induces tumor immunity J Exp Med 1998; 188:1553-61.
Zugel. U . et al , Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. J Immunol. 1998 161(4): p. 1705-9.
Pinilla-Ibarz, J , et al . Synthetic analogue bcr/abl fusion peptides improve class I Immunogenicity to the native protein Blood. 2000 96(11): p. 510a-510a.
Clay TM. Custer MC, McKee MD. Parkhurst M, Robbins PF. Kerstann K. et al Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999:162: 1749-55.
Parkhurst MR, Saigalier ML. Southwood S. Robbins PF, Setle A, Rosenberg SA. et al Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A 0201-binding residues. J Immunol 1996; 157:2539-48.
Rosenberg SA. Yang JC. Schwartzentruber DJ, Hwu P. Marincola FM, Topalian SL, et al Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 1998; 4:321-7.
Slansky JE, Rattis FM, Boyd LF. Fahmy T. Jaffee EM, Schneck JP, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex immunity 2000; 13:529-38.
Nicholson LB, Waldner H. Carrizosa AM, Sette A, Collins M. Kuchroo VK Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity Proc Natl Acad Sci USA 1998:95:264-9.
Valmori D, Fonteneau JF, Valitutti S. Gervois N. Dunbar R. Lienard D, et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues Int Immunol 1999;1971-80.
Kessler et al, Effects of epitope modification on T cell receptor-ligand binding and antigen recognition by seven H-2Kd-restricted cytotoxic T lymphocyte clones specific for a photoreactive peptide derivative. J Exp Med. Feb. 17, 1997;185(4):629-40.

Affiliated with

Also associated with

Rating

Synthetic HLA binding peptide analogues and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Synthetic HLA binding peptide analogues and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic HLA binding peptide analogues and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4106086